Charles Loeb, MD
Urology · Newport Beach, CANPI 1750878997
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,151 of the $52,794 with a category attached, or 95.0%. Boston Scientific accounts for 97.4% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $50,128, more than ten times the $33 reported in 2021. Among urology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 59 payments — averaging $894.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$51K
- Endo Pharmaceuticals Inc.$476
- Coloplast$298
- Antares Pharma, Inc.$268
- Endo USA, Inc.$122
- Medtronic$107
- plus $82 from 2 others
What the payments were for
- Grants$50,15195%
- Food & beverage$2,6435%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 34 | $51,441 |
| Endo Pharmaceuticals Inc. | 5 | $476 |
| Coloplast | 6 | $298 |
| Antares Pharma, Inc. | 5 | $268 |
| Endo USA, Inc. | 5 | $122 |
| Medtronic | 1 | $107 |
| Halozyme Inc | 2 | $56 |
| Urogen Pharma, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,794 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone | 14 | $2,644 |
| Testosterone Cypionate | 54 | $1,945 |
| Tamsulosin Hcl | 39 | $574 |
| Cefdinir | 11 | $180 |
| Anastrozole | 16 | $87 |
| Meloxicam | 12 | $10 |
| Tramadol Hcl | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Other urology in Newport Beach
- Jeffrey BassettNewport Beach$76K
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.